Close Menu

NEW YORK – Angiocare will distribute Spartan Bioscience's test for CYP2C19 mutations, the firms announced on Thursday.

The deal covers the Netherlands, where Angiocare is based, although it may eventually cover other geographies, a spokesperson for Spartan Bio said. She declined to disclose further details.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.